Establishment of a Neutrophil elastase Activity home test for the Better managem...
Establishment of a Neutrophil elastase Activity home test for the Better management and treatment of Lung Exacerbations
Chronic obstructive airways disease (COPD) is a leading cause of death of increasing prevalence worldwide and is characterised by progressive airflow reduction, breathing difficulties and irreversible lung damage. Management of C...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto ENABLE
Duración del proyecto: 6 meses
Fecha Inicio: 2014-09-26
Fecha Fin: 2015-03-31
Líder del proyecto
PROAXSIS LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Chronic obstructive airways disease (COPD) is a leading cause of death of increasing prevalence worldwide and is characterised by progressive airflow reduction, breathing difficulties and irreversible lung damage. Management of COPD varies extensively, with patients not receiving proactive disease management at greater risk of poorer outcomes. Routine measurement of an active protease (enzyme) biomarker called neutrophil elastase (NE) will empower clinicians and patients to adopt proactive approaches to disease management and treatment, reducing exacerbations and emergency hospital admissions.
Our goal is therefore to develop a novel, simple to use ‘Point-of-Care’ (PoC) test that will improve patient outcome and reduce the clinical, societal and economic burdens associated with chronic respiratory disease (CRD). The activity of NE (NEa) in the airways is known to correlate with the severity of several CRDs such as COPD, cystic fibrosis (CF) and bronchiectasis, and importantly is highly predictive of infection and an early marker of exacerbation. Our novel device, NEATstikTM (Neutrophil Elastase Airways Test), will enable the rapid measurement of NEa at PoC and has been designed for home use (patient self-management) in mind, with a view to remote monitoring. It is expected that this test will help to improve patient management and outcome, with the ultimate goal of reducing the individual, European and global burden of COPD.
This phase 1 proposal is to provide a feasibility assessment which will maximise the potential for success the clinical validation of NEATstikTM, a PoC device that will enable the proactive management of chronic respiratory diseases such as COPD.